When Two Plus Four Does Not Equal Six: Combining Computational and Functional Evidence to Classify BRCA1 Key Domain Missense Substitutions.

Author List: Scott T. Pew,[1] Madison B. Wiffler,[2] Alun Thomas,[3] Julie L. Boyle,[4,5] Melissa S. Cline,[6] Nicola J. Camp,[5,7] David E. Goldgar,[5,8] Sean V. Tavtigian[1,5*]

Affiliations:

1. Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, Utah, 84112, USA

2. Department of Neurobiology, University of Utah School of Medicine, Salt Lake City, Utah, 84112, USA

3. Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, 84108, USA

4. Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah, 84108, USA

5. Huntsman Cancer Institute, Salt Lake City, Utah, 84108, USA

6. UC Santa Cruz Genomics Institute, Genomics, University of California, Santa Cruz, CA, 95064, USA

7. Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, 84108, USA

8. Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, 84108, USA

*   Correspondence: sean.tavtigian@hci.utah.edu.

ABSTRACT

Classification of genetic variants remains an obstacle to realizing the full potential of clinical genetic sequencing. Because of their ability to interrogate large numbers of variants, multiplexed assays of variant effect (MAVEs) and computational tools are viewed as a critical part of the solution to variant classification uncertainty. However, the (joint) performance of these assays and tools on novel variants has not been established. Transformation of the qualitative classification guidelines developed by the American College of Medical Genetics and Genomics (ACMG) into a quantitative Bayesian point system enables empirical validation of strength of evidence assigned to evidence criteria. Here, we derived a maximum likelihood estimate (MLE) model that converts frequentist odds ratios calculated from case-control data to proportions pathogenic and applied this model to functional assays, alone and in combination with computational tools across several domains of *BRCA1*. Furthermore, we defined exceptionally conserved ancestral residues (ECARs) and interrogated the performance of assays and tools at these residues in *BRCA1*. We found that missense substitutions in *BRCA1* that fall at ECARs are disproportionately likely to be pathogenic with effect sizes similar to that of protein truncating variants. In contrast, for substitutions falling at non-ECAR positions, concordant predictions of pathogenicity from functional assay and computational tool often fail to meet the additive assumptions of strength in ACMG guidelines. Thus, collectively, we conclude that strengths of evidence assigned by expert opinion in the ACMG guidelines are not universally applicable and require empirical validation.

INTRODUCTION:

ClinVar recently celebrated its 10th anniversary. In that time, as clinical sequencing has become more prevalent, the number of variants cataloged has grown from approximately 27,000 to well over 2 million. Of these 2 million variants, approximately 1.3 million are single nucleotide missense variants (excluding synonymous and nonsense variants), of which roughly 75% remain unclassified (~990,000 variants) [1]. Realizing the full potential of clinical genetic sequencing relies on the ability to accurately and efficiently classify these variants into a realistic continuum from pathogenic to benign. To that end, many multiplexed assays of variant effect (MAVE) and computational tools have been developed. However, the accuracy of these assays and tools, used independently and in combination with one another, towards classifying novel variants identified during sequencing remains to be established.

In 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published guidelines that relied on expert opinion to assign strength of evidence to the various evidence criteria used in sequence variant classification [2]. Subsequently, this approach was found to be compatible with a Bayesian point system where the qualitative assessments of evidence strength categories (supporting, moderate, strong, etc.) were converted to quantitative assertions of odds of pathogenicity (OP) [3, 4]. Shifting to the Bayesian point system makes possible objective evaluation of the strength of evidence the various evidence criteria actually provide. For example, it was recently demonstrated that several computational tools exceeded the qualitative threshold of "supporting" evidence in favor of benignity or pathogenicity and were able to provide "moderate", and in some cases "strong" evidence in favor of benignity or pathogenicity [5].

In the 2015 ACMG/AMP guidelines, well-established functional assays were qualitatively assigned the ability to provide "strong" evidence in favor of pathogenicity or benignity [6]. In the Bayesian point system, this translates to +4 points (18.7:1 odds in favor of pathogenicity) or -4 points (0.053:1 odds in favor of pathogenicity). Yet, limited work has been performed to

quantitatively evaluate the strength of evidence that functional assays provide. As these assays

are not a direct measure of human health, an important step towards applying a specific

functional assay's results to variant classification is validation of the assay's calibration against

human subjects' data from the disease in question.

Furthermore, the 2015 guidelines provided combining rules that prescribed combinations

of different categories of evidence that could move a variant towards classification as

pathogenic or benign. Implicit in the original guidelines, and explicitly stated in the subsequent

work that transformed the guidelines into a Bayesian framework, is the idea that combining

evidence changes the estimate of a sequence variant's probability of pathogenicity. In a

previous publication [7], we noted that a majority of variants in the *BRCA1* RING domain could be

classified by using computational predictions (ACMG codes: PP3/BP4), whether or not a variant

fell at a canonical residue (ACMG code: PM1), functional assay predictions (ACMG codes:

PS3/BS3), and minimal human subjects observational data (ACMG codes: PS4, PM2, BS1).

This led to our conclusion that validation work is needed to ensure that the strength assigned to

these types of evidence was accurate and that addition of Bayesian points associated with

these evidence types was the correct mathematical operation.

As a step towards an empirical test, we derive a maximum likelihood estimate (MLE)

expression for the proportion of variants that are pathogenic within an analytically defined pool.

This model transforms odds ratios (OR) from human subjects' case-control data into a

proportion pathogenic which can then be used to objectively test the strength of evidence a

particular category of evidence provides. Subsequently, we demonstrate two important

applications for such a model using case-control data from *BRCA1* as a test case. First, we use

our model to determine if evidence from several functional assays developed for *BRCA1*

generate the strength of evidence assumed in the 2015 ACMG/AMP guidelines. Second, we

explore the impact of combining functional assay, canonical residue (which we rename

"exceptionally conserved ancestral residues" (ECARs)), and computational tool data to see if

doing so changes the proportion pathogenic of analytical subsets of variants in a way that

matches the additivity expectations set forth in the Bayesian adaptation of the 2015

classification guidelines (Figure 1). Such an approach allows for the quantitative validation of

the qualitative assumptions proposed in variant classification guidelines, a step that is currently

lacking for many evidence criteria used in variant classification.

METHODS:

<u>Maximum Likelihood Estimate of Proportion Pathogenic</u>

In addition to the assumptions in the Bayesian point system ($OP = 81^{\frac{ACMG\ points}{6}}$, prior

probability of pathogenicity = 0.102, points are log odds and therefore additive), this approach

relies on several other assumptions:

1. The OR of a pool of truncating variants in loss of function susceptibility genes

provides a "standard candle" by which one can measure the magnitude of effect of a

given analytically defined pool of variants.

2. An analytically defined pool of variants with an OR similar to that of a pool of

truncating variants consists almost entirely of variants that are pathogenic with an

effect size approximately equal to that of the truncating variants.

3. An analytically defined pool of variants with an OR near 1.0 consists almost entirely

of benign variants.

4. Analytically defined pools of variants with an OR between 1.0 and the OR of

truncating variants can be modeled as a two-component mixture of benign and

pathogenic variants. This assumption is debatable, but importantly, is also testable.

The full derivation of the maximum likelihood estimate model is presented in the

Supplemental Methods. In brief, our model estimates the proportion of observed variants that

are pathogenic, q, from the proportion of all variants that are pathogenic, p, the number of

cases, n, the number of controls, m, the population frequency of disease among individuals who

do not carry a pathogenic variant, δ, and the frequency of disease among individuals who are

carriers of a pathogenic variant, δ_1, as shown in Equation 1:

129
$$\hat{q} \; = \; \frac{\hat{p}\left[n\hat{\delta}(1-\delta_1) + \; m\left(1-\hat{\delta}\right)\delta_1\right]}{\hat{p}\left[n\hat{\delta}(1-\delta_1) + \; m\left(1-\hat{\delta}\right)\delta_1\right] + \; (1-\hat{p})\hat{\delta}\left(1-\hat{\delta}\right)(n+m)} \tag{1}$$

In addition to the variables listed above, our MLE model requires input values for an

odds ratio threshold at which all variants are assumed to be pathogenic. For the odds ratio

threshold in our analysis, truncating variants observed in our case-control dataset were

tabulated and frequentist odds ratios for breast and ovarian cancers were calculated for these

groups of variants (16.2, 95% CI: 12.7 – 20.8 for breast cancer and 46.4, 95% CI: 35.7 – 60.7

for ovarian cancer). To evaluate the prediction of benign variants we used an alternative OR

ceiling chosen to match the threshold of moderate-risk variants (OR = 2.0 for breast cancer and

OR = 2.9 for ovarian cancer), which was calculated to be inflated to 2.31 and 3.83 in our family

history enriched case-control dataset [8, 9]. The general population frequency of cancer used in

the analysis was 0.125 for breast cancer, and 0.011 for ovarian cancer [10, 11].

<u>Identification of Exceptionally Conserved Ancestral Residues in BRCA1 / BARD1</u>

To find evolutionarily distant BRCA1/BARD1 homologs, we started with two alignments,

one of the RING domains of BRCA1 and BARD1 from *Homo sapiens* and *Strongylocentrotus*

purpuratus and a second of the corresponding tandem BRCT (tBRCT) domains. These

alignments were prepared using the structure-guided 3D-Coffee/Expresso mode from the T-

coffee suite of sequence alignment tools [12, 13]. The two resulting alignments were used with

hmmsearch to scan phylogenetically defined subsets of the reference proteome database

maintained at the HMMER website [14]. Hits were defined as gene models with high-scoring

matches to both the RING and tandem BRCT alignments.

At the first round, hits from Placozoa and single celled Holozoans were included, the

alignments rebuilt, and then trimmed back to include clear *BRCA1* and *BARD1* orthologs from

Trichoplax and *Salpingoeca*. The process was iterated to obtain and include homologs from the

Fungi and then reiterated to obtain and include homologs from three additional eukaryotic

supergroups: Archaeplastida, SAR, and Discoba.

To prepare the final alignments and then define exceptionally conserved ancestral

residues (ECARs), we stratified the hits into a group of *BARD1* and relatively *BARD1*-like hits

and a second group of *BRCA1* and relatively *BRCA1*-like groups; ambiguous hits were placed in

the *BRCA1*-like group. As before, RING and tBRCT alignments were prepared using 3D-

Coffee/Expresso. Then the BRCA1 and BARD1 alignments were aligned to each other by

introducing gaps across the whole BRCA1 or whole BARD1 alignment, i.e., without modifying

the within-group alignments. The tBRCT alignments were then appended to the RING domain

alignments. Finally, ECARs were defined as (a) positions that were invariant in our existing

metazoan BRCA1 and BARD1 alignments used with Align-GVGD [15, 16], and either (b) also

invariant in the new multi-supergroup alignments or (c) had just one conservative substitution

(i.e., Grantham Variation <65) in the new multi-supergoup alignment.

<u>Functional Assay Results and Computational Predictions</u>

Functional assay scores were obtained from three separate assays that interrogate

missense variants in various domains of *BRCA1*. These assays were: the 2018 Findlay et al.

saturation genome editing (SGE) assay that interrogated missense and splice junction variants

in the RING and tBRCT domain of *BRCA1* [17], the 2022 Clark et al. mammalian-2-hybrid (M2H)

assay performed by our laboratory that evaluated missense variants in the RING domain of

BRCA1 [7], and the 2023 Nagy et al. homology-directed repair (HDR) assay that evaluated

missense variants in the coiled-coil domain of *BRCA1* [18]. The M2H and SGE assays were

selected due to their nearly comprehensive evaluation of all possible snMS variants in the RING

and/or tBRCT domains of BRCA1. The HDR assay was selected because it interrogated the

coiled-coil domain which is considered a clinically import functional domain[19]. Scores for these

assays were downloaded from MaveDB (SGE and M2H) [20] or from the publication [18].

Thresholds for functional, indeterminate and non-functional variants were used as defined by

the relevant publication. We used the calibrated scores for each assay in our analysis because

these are the thresholds that are likely to be used during clinical variant classification.

Computational tool scores for BayesDel no-AF [21], REVEL [22], and VEST4 [23] were

obtained from the database for Non-synonymous Functional Predictions (dbNSFP) via

Ensembl's web-based Variant Effect Predictor (VEP) [24, 25]. Computational scores for MutPred2

were obtained by downloading a local copy of the software[26]. Scores for AlphaMissense were

downloaded from the original publication [27]. Scores for Align-GVGD (A-GVGD) [28, 29] were

obtained from agvgd.hci.utah.edu using the Human to Sea Urchin alignment. Thresholds for

pathogenic and benign for AlphaMissense, BayesDel, MutPred2, REVEL, and VEST4 were the

supporting pathogenic and supporting benign thresholds from recent calibrations of these tools[5,

30]. Align-GVGD, predictions with a score of C0 were interpreted as predicted benign,

intermediate scores as indeterminate, and scores of C65 were interpreted as predicted

pathogenic. AlphaMissense, BayesDel, MutPred2, REVEL, and VEST4 were selected because

they demonstrated the ability to provide strong evidence in favor of pathogenicity in recent

calibration studies[5, 30] and some of these tools are often used by Variant Curation Expert Panels

(VCEP). While the scales for each tool may differ, the individual thresholds used in this work are

those established in Pejaver et al. to be sufficient for supporting evidence for both benign and

pathogenic variants in the ACMG classification framework. A-GVGD has previously been

demonstrated to perform well in *BRCA1*[15].

Estimate of ACMG Points

We interpreted the MLE proportion pathogenic as a posterior probability, PP

(represented as q in the supplemental text and Equation 1), of the variants in the analytical

subset being pathogenic and we thus converted this estimate to the appropriate ACMG point

value via an OP using a prior probability (P_1) of 0.102[4]. Proportions pathogenic were calculated

separately for each cancer type using our MLE model, converted to odds of pathogenicity using

Equation 2 below, and then combined using a weighted geometric mean based on the number

of individuals in the breast cancer case control group and ovarian cancer case control group.

This new estimate of odds of pathogenicity was subsequently converted back to a proportion

pathogenic to display in Tables 2 – 4 and converted to ACMG points using Equation 3[4]. When

assigning ACMG points from the estimated proportion pathogenic, the points that could be

awarded were limited to the maximum values prescribed in the ACMG guidelines unless

otherwise noted [2, 4].

216
$$PP = (OP \times P_1) \div [(OP - 1) \times P_1 + 1] \qquad (2)$$

217
$$OP = 81^{\frac{ACMG\ points}{6}} \qquad (3)$$

<u>Case and Control Count Sources and Odds Ratio Calculations</u>

Human subjects' data were obtained from Ambry Genetics and Myriad Genetics. Control

counts are from the non-cancer cohort of gnomAD v2 exomes and gnomAD v3 genomes[31, 32].

Ethnicity for this dataset was split into four groups: non-Finnish European (NFE), Ashkenazi

Jewish, Finnish, and all others. Ashkenazi Jewish and Finnish individuals were removed due to

strong founder effects in these populations. Individuals from Ambry and Myriad were considered

breast cancer cases if they had breast cancer and did not have ovarian cancer. Individuals from

Ambry and Myriad were considered ovarian cancer cases if they either had ovarian cancer or

ovarian and breast cancer.

The Ambry dataset initially included data generated by Ambry Genetics from multi-gene

sequencing panels for 165,031 individuals "exempted from review by the Western Institutional

Review Board" [33]. Filters were applied to remove those individuals without breast or ovarian

cancer, individuals who lacked *BRCA1* sequence data, individuals of Ashkenazi Jewish or

Finnish ancestry, and individuals with pathogenic or likely pathogenic variants in *TP53*, *BRCA2*,

and *PALB2*. This resulted in a final dataset of 98,111 individuals, 66,672 (68%) of which were of

NFE ethnicity and 31,439 (32%) of other ethnicity. Of individuals of NFE ethnicity, 57,431 (86%)

had breast cancer and 9,241 (14%) had ovarian cancer. Of individuals of other ethnicity, 28,114

(89%) had breast cancer and 3,325 (11%) had ovarian cancer.　2,970 individuals had variants in

BRCA1: 1,266 (43%) individuals of NFE ethnicity who had breast cancer, 452 (15%) individuals

of NFE ethnicity who had ovarian cancer, 1,013 (34%) individuals of other ethnicity who had

breast cancer, and 239 (8%) individuals of other ethnicity who had ovarian cancer. 477

individuals had missense variants that fell within the RING (amino acids 1-100), coiled-coil

(amino acids 1,280-1,576), or tBRCT domain (amino acids 1,650-1,863): 118 (25%) individuals

of NFE ethnicity who had breast cancer, 155 (32%) individuals of other ethnicity who had breast

cancer, 123 (26%) individuals of NFE ethnicity who had ovarian cancer, and 81(17%) individuals

of other ethnicity who had ovarian cancer.

The Myriad dataset initially included data generated by full-sequence BRCA1/2 tests

performed by Myriad Genetics from 60,607 individuals. For these, a test request form must have

been completed by the ordering health care provider, and the form must have been signed by

an appropriate individual indicating that "informed consent has been signed and is on file" [15, 33,

[34]. Filters were applied to remove those individuals without breast or ovarian cancer, individuals

who lacked *BRCA1* sequence data, individuals of Ashkenazi Jewish or Finnish ancestry, and

individuals with pathogenic or likely pathogenic variants in *BRCA2*. This resulted in a final

dataset of 35,088 individuals, 25,653 (73%) of which were of NFE ethnicity and 9,435 (27%) of

other ethnicity. Of individuals of NFE ethnicity, 22,504 (88%) had breast cancer and 3,149 (12%)

had ovarian cancer. Of individuals of other ethnicity, 8,347 (88%) had breast cancer and 1,088

(12%) had ovarian cancer. 4,005 individuals had variants in *BRCA1*: 2,231(56%) individuals of

NFE ethnicity who had breast cancer, 639 (16%) individuals of NFE ethnicity who had ovarian

cancer, 904 (22%) individuals of other ethnicity who had breast cancer, and 231 (6%) individuals

of other ethnicity who had ovarian cancer. 524 had missense variants that fell within the RING,

coiled-coil, or tBRCT domain: 289 (55%) individuals of NFE ethnicity who had breast cancer, 83

(16%) individuals of NFE ethnicity who had ovarian cancer, 124 (24%) individuals of other

ethnicity who had ovarian cancer, and 28 (5%) individuals of other ethnicity who had ovarian

cancer.

The gnomAD dataset is a composite of non-overlapping v2 non-cancer exomes and v3

non-cancer genomes that initially included 192,502 individuals. Filters were applied to remove

individuals of Finnish or Ashkenazi Jewish ancestry and to remove common missense variants

(allele frequency > 0.000271). This resulted in a final dataset of 169,933 individuals: 84,396

(50%) individuals of NFE ethnicity and 85,537 (50%) individuals of other ethnicity. 644

individuals had missense variants that fell within the *BRCA1* RING, coiled-coil, or tBRCT

domain: 264 (41%) individuals of NFE ethnicity and 380 (59%) individuals of other ethnicity.

Combining these datasets resulted in a final dataset of 133,199 breast and ovarian

cases from Ambry and Myriad and 169,933 controls from gnomAD v2 and v3.

After filtering, the data for *BRCA1* were formatted into a table that indicated the ethnicity

of the individual, whether an individual was a case or control, how the variant was classified by

each functional assay and computational tool, and whether the variant fell at an ECAR.

Logistic regression was performed using R studio to calculate frequentist odds ratios for

each stratum (functional, indeterminate, loss-of-function (LOF) all, LOF-ECAR, LOF-other) of

the functional assays included in our analysis. Odds ratios were calculated similarly for strata

that resulted in combining SGE functional assay results and computational tool predictions.

Proportions pathogenic were calculated using a custom R script. Following logistic regression,

the Wald test was performed to determine statistical significance between strata in each

analysis.

To determine if combining computational tool predictions to functional assay predictions

was statistically significant, multivariate logistic regression was performed using combinations of

the SGE functional assay result (functional or LOF) and computational tool predictions (benign

or pathogenic) for each tool analyzed in our study.

RESULTS:

<u>Exceptionally Conserved Ancestral Residues in *BRCA1* / *BARD1*</u>

BRCA1, *BARD1*, and homologs that have been studied in the Archaeplastida are

thought to have evolved from a common ancestor gene with a 5' RING domain and 3' tandem

BRCT (tBRCT) domain that was present in an ancient eukaryote before the divergence of

Amorphea and Archaeplastida [35]. Protein multiple sequence alignment (PMSA) based

hmmsearch [14] identified clear *BRCA1* and *BARD1* orthologs in *Trichoplax* and more distantly

related single-celled members of Holozoa, plus homologs (some of which may be true

orthologs) in the Holomycota, Archaeplastida, SAR, and Discoba. Although the root of the

eukaryotic phylogeny remains unclear [36, 37], the resulting PMSA should be sufficient to identify

positions in human *BRCA1* and *BARD1* where the amino acid present in the two human

sequences has been inherited identical by descent from a common ancestor gene and is under

constraint in the Amorphea and 2-3 additional eukaryotic supergroups. We identified 14 such

residues: the 8 residues that define the C3HC4 RING motif plus 6 additional residues in the

tBRCT domain (Table 1, Figure S1), and hereafter refer to them as Exceptionally Conserved

Ancestral Residues (ECARs).

Of the 82 possible snMSs at ECARs, 78 resulted in a non-functional assay result via the

SGE assay. The four exceptions were C24F, C61R, T1700S (which was not interrogated in the

SGE assay), and W1718S. C24F, C61R, and W1718S had indeterminate results in the SGE

assay, however, C24F and C61R were scored as loss of function in the M2H assay.

Using the pathogenic strong thresholds established in Pejaver et al, we also tabulated

the number of substitutions at ECARs that were extreme enough to receive +4 ACMG points

from computational tools (Table 1). MutPred2 predicted 0 of the possible ECAR substitutions to

be extreme enough to receive +4 ACMG points. BayesDel predicted 56 of the 82 possible

substitutions to be extreme enough for +4 ACMG points, and these constituted 56 of the 73

such RING and tBRCT +4 results called by BayesDel. AlphaMissense, REVEL, and VEST4 had

totals that fell between MutPred2 and BayesDel.

A separate analysis was performed using the BayesDel threshold prescribed in the

ENIGMA BRCA1 VCEP (henceforth Bayes-Del VCEP) guidelines ($\geq$ 0.28) as well as for Align-

GVGD using C65 as a pathogenic prediction threshold[19]. Under these parameters, which only

generate predictions of supporting benign, indeterminate, or supporting pathiogenic, many more

of the ECARs identified in the tBRCT domains were predicted to be pathogenic (Table 1). A

summary of computational tool performance at ECAR positions and individual scores for each

substitution are available in Table S1 and the supplemental spreadsheet.

Functional Assay Performance

To analyze the performance of functional assays, an OR threshold set to that of the OR

of nonsense substitutions observed in our case control dataset for each cancer type was used,

which was 16.2 (95% CI: 12.7 – 20.7) for breast cancer and 46.4 (95% CI: 35.7 – 60.7) for

ovarian cancer. The combined proportion pathogenic of the breast cancer and ovarian cancer

analysis and subsequent ACMG points of functional assay performance using the nonsense

substitution OR thresholds are presented in Table 2. ORs and proportions pathogenic by

cancer type are presented in the supplemental text.   As stated in the Methods section, ACMG

points awarded are limited to the maximum number of points outlined in the ACMG guidelines

and subsequent transformation to a Bayesian framework.

In the M2H assay, which interrogates variants in the RING domain of BRCA1, variants

that were functional and were observed in our case control dataset yielded an adjusted OR

close to 1 (1.42, 95% CI: 1.01 – 1.99 for breast cancer and 2.45, 95% CI: 1.41 – 4.24 for

ovarian cancer) indicating a group of variants composed almost entirely of benign variants. The

combined proportion pathogenic for this group was estimated to be 0.04 which translates to -1

points in the ACMG points system. There were insufficient observations for variants that were

categorized as indeterminate to compute an OR or a proportion pathogenic. The group of all

variants that were non-functional and observed in our dataset had an adjusted OR of 19.9 (95%

CI: 11.3 – 35.0) for breast cancer and 40.0 (95% CI: 21.5 – 73.1) for ovarian cancer which is

similar to that of nonsense substitutions for each cancer type in our dataset, indicating a group

consisting of mostly pathogenic variants. This analytical subset had a combined proportion

pathogenic of 0.99, which would be assigned the full +4 points that are available for non-

functional assay results in the ACMG guidelines.

In addition to evaluating the strength of evidence of a single evidence category, our

model can also test the strength of combined evidence categories. To this end, the non-

functional variants from the M2H assay were stratified into two groups: variants that fell at the

ECARs identified from the PMSA (ACMG code: PM1), and all other residues. For variants that

were non-functional and fell at an ECAR, the computed OR was 22.0 (95% CI: 12.0 – 40.6) for

breast cancer and 40.8 (95% CI: 21.1 – 79.0) for ovarian cancer, slightly higher than the group

of all non-functional variants and indicating a subset of variants with similar risk to that of

truncating variants. The computed combined proportion pathogenic was 1.00. Combining the

+4 points from functional assay and +2 points available from ECARs (PM1), results in +6 points

for this group of variants. Thus, using these two evidence criteria alone, these variants reach

the Likely Pathogenic threshold.

The computed OR for non-functional variants that fell at other residues was 7.82 (95%

CI: 1.68 – 36.3) for breast cancer and 32.9 (95% CI: 6.37 – 170.1) for ovarian cancer, indicating

that this group of variants confers less risk than those that are non-functional and fall at an

ECAR. The combined proportion pathogenic for the non-functional variants that fell at other

residues was 0.70, sufficient for +4 points from functional assay. In the absence of other

evidence, this group would remain variants of uncertain significance (VUS).

The SGE assay, which evaluated variants across the RING and tBRCT domains of

BRCA1, had similar results to the M2H assay. The group of variants that were functional via

SGE yielded an OR close to 1 (1.11, 95% CI: 0.91 – 1.36 for breast cancer and 1.34, 95% CI:

0.90 – 2.01 for ovarian cancer) and a combined proportion pathogenic of 0.00, which would

qualify for the full -4 points available from a functional assay result. For variants that were non-

functional, the SGE assay had an OR of 15.7 (95% CI: 11.1 – 22.0) for breast cancer and 35.1

(95% CI: 24.0 – 51.2) for ovarian cancer and a combined proportion pathogenic of 0.92 which

would confer the full +4 points for these variants. Stratification of non-functional variants at

ECARs versus non-functional variants at other residues again demonstrates that non-functional

variants at ECARs have enough strength of evidence to reach the Likely Pathogenic threshold.

The ORs for non-functional variants at ECARs were 23.6 (95% CI: 12.9 – 43.3) for breast

cancer and 42.3 (95% CI: 21.9 – 81.7) for ovarian cancer with a combined proportion

pathogenic of 1.00, sufficient for +6 ACMG points. The ORs for non-functional variants at non-

ECAR positions were 12.2 (95% CI: 8.07 – 18.5) for breast cancer and 31.7 (95% CI: 19.9 –

50.5) for ovarian cancer with a combined proportion pathogenic of 0.76, which qualifies for +4

ACMG points. Moreover, the risk estimates for non-functional variants at ECAR versus non-

ECAR positions were distinct from each other, P=0.031 in a two-sided 3x2 FET test.

Whereas the M2H and SGE assays largely confirmed the assumptions of strength of

evidence in the ACMG guidelines, the results from the HDR assay in the coiled-coil domain of

BRCA1 produce a different result. The ORs for the functional group of variants were 1.87 (95%

CI: 1.11 – 3.15) for breast cancer and 2.04 (95% CI: 0.77 – 5.39) for ovarian cancer with a

combined proportion pathogenic of 0.08 translating to 0 ACMG points. The variants that were

non-functional via the HDR assay had an OR of 1.58 (95% CI: 0.09 – 26.8) for breast cancer

and insufficient observations to calculate an OR for ovarian cancer, with an identical proportion

pathogenic of 0.08 and 0 ACMG points. It is noted that there were few observations in our

case-control dataset that both fell within this domain and were included in the functional assay.

Additionally, many of the variants interrogated by this assay do not appear to be attainable via a

single nucleotide substitution to the canonical *BRCA1* transcript, which is the type of substitution

that is the primary focus of this analysis.

Due to these limitations, a separate analysis was performed focusing on structurally

informed predictions of damage to coiled-coil interactions at the alpha helix spanning amino

acids 1,400-1,418, i.e., non-conservative substitutions at the helix *a* and *d* positions plus any

substitutions to proline falling in the same interval. With only one observation in a case

(p.L1407R) against four control observations (one each for p.M1400K, p.L1404R, p.L1407H,

and p.L1414P), the observational evidence weighs against the hypothesis that missense

substitutions in this domain are pathogenic (Table 2, final line).

<u>Combining SGE Functional Results and Computational Predictions</u>

To explore the impact of combining functional assay results and computational tool

predictions variants from the SGE assay were stratified by computational prediction

(pathogenic, indeterminate, and benign) from seven computational tools (Align-GVGD,

AlphaMissense, BayesDel, BayesDel-VCEP, MutPred2, REVEL, and VEST4) using thresholds

outlined in Pejaver *et al.*[5, 30] or those stated in the Methods section. This analysis was

performed only on results from the SGE assay which interrogated both the RING and tBRCT

domains of *BRCA1* and thus had sufficient observations for stratification. To focus on the impact

of combining functional assays and computational tool predictions on variant classification, the

combined proportions pathogenic and subsequent ACMG points are presented in Tables 3 and

4. ORs and proportions pathogenic for each stratum and cancer type are presented in the

supplemental text (Tables S3 – S6. Multivariate logistic regression was also performed to

determine if adding computational tool predictions to functional assay results was statistically

significant (Table S7).

<u>Combining Assay Results of Non-functional with Computational Predictions for Substitutions</u>

<u>Falling at Non-ECAR Positions</u>

The proportion pathogenic for the group of variants that were categorized as non-

functional via the SGE assay and did not fall at ECARs was 0.76, corresponding to +4 ACMG

points, as stated previously. The ORs for this group of variants for breast and ovarian cancer are

12.2 (95% C.I. 8.07 – 18.5) and 31.7 (19.9 – 50.5) respectively. Stratifying these variants by

computational prediction allows evaluation of the effect of combining functional assay and

computational prediction data toward variant classification (Table 3). It should be noted that if

the computational predictions unanimously agreed with the functional assay result, the OR,

estimated proportion pathogenic, and ACMG points would remain unchanged after adding in

evidence from computational tools. Thus, any utility of computational predictions in this analysis

emerges from the ability of the computational tool to accurately disagree with – and thereby

stratify – the functional assay result.

For four of the computational tools evaluated, Align-GVGD, AlphaMissense MutPred2,

and VEST4, the benign and/or indeterminate prediction yielded a lower proportion pathogenic

and lower ACMG point score than the overall pool of SGE non-ECAR, non-functional

substitutions. For Align-GVGD and AlphaMissense, this effect of accurate disagreement was

strong enough that concordant prediction of pathogenicity from the SGE assay and

computational tool resulted in a higher proportion pathogenic and higher ACMG point score

(+5). Align-GVGD was the only computational tool that successfully stratified the group of non-

functional assay results into three corresponding strata that matched the ACMG expectations.

The corresponding ORs for concordant predictions of pathogenicity were 13.9 (95% C.I. 7.39 –

26.1) for breast cancer and 40.2 (95% C.I. 20.1 – 80.3) for ovarian cancer. When Align-GVGD

disagreed with the functional assay and predicted variant to be benign the ORs were 6.06 (95%

C.I. 1.98 – 18.5) and 22.1 (95% C.I. 6.58 – 74.2) for breast and ovarian cancer respectively.

In contrast, BayesDel and REVEL produced an unexpected reverse stratification, with a

higher proportion pathogenic and higher ACMG point score in their indeterminate or benign

prediction than in their pathogenic prediction. Correlation between these two - even in failure - is

not unexpected as both are meta-callers, incorporating predictions from individual callers into a

weighted overall score, and share several of the same individual components [21, 22].

<u>Combining Assay Results of Functional with Computational Predictions for Substitutions Falling</u>

<u>at Non-ECAR Positions</u>

For the analysis of variants that were functionally normal via SGE and did not fall at

ECARs, an alternative OR ceiling was set at the threshold for moderate-risk variants to evaluate

evidence against pathogenicity (OR = 2.0 for breast cancer and 2.9 for ovarian cancer in a

general population[8, 9], which are inflated to 2.31 and 3.83 respectively in our dataset). For the

SGE assay, functional variants had an estimated proportion pathogenic of 0.00, sufficient for the

-4 ACMG points allowable from functional assays. The OR for breast cancer for this group of

variants was 1.11 (95% C.I. 0.91 – 1.36) and 1.34 (95% C.I. 0.90 – 2.01) for ovarian cancer.

The results of stratification by computational tool are presented in Table 4; as in Table 3, the

utility of computational predictions in this analysis emerges from the ability of a computational

tool to accurately disagree with – and thereby stratify – the functional assay result. In this

analysis, all of the computational tools were to some extent successful, with their predictions of

pathogenicity yielding a higher proportion pathogenic and higher ACMG point score than the

overall pool of SGE functional substitutions.

However, BayesDel and REVEL made very few predictions of benignity even though this

group of variants were functional in the SGE assay and had ensemble odds ratios and

proportions pathogenic consistent with the vast majority actually being benign. On the other

hand, for Align-GVGD, AlphaMissense, BayesDel (with and without the VCEP calibration), and

VEST4 the effect of discordant prediction of benignity from the SGE assay and pathogenicity by

the computational tool was a substantial pool of missense substitutions with an ACMG point

score of +1 or higher – though it must be held in mind that these positive scores represent

modest evidence in favor of pathogenicity as moderate-risk variants, not as high-risk variants.

This is evidenced by the magnitude of the ORs generated for the group of variants predicted to

be pathogenic by Align-GVGD: 2.71 (95% C.I. 1.09 – 6.72) for breast cancer and 3.73 (95% C.I.

0.77 – 18.1) for ovarian cancer. Corresponding ORs for the other tools evaluated are presented

in the supplemental text (Tables S5 – S6).

Finally, results from multivariate logistic regression substantiate the observed trend in

proportions pathogenic and ACMG points provided by computational tool stratification.

Predictions from three tools, Align-GVGD, AlphaMissense, and VEST4 were statistically

significant (p-values low enough to overcome the intrinsic multiple test) when added to

functional assay results. Predictions from BayesDel, BayesDel-VCEP, MutPred2, and REVEL,

did not improve the regression model compared to a model that included only the functional

assay (Table S7). Note that while adding the results of some computational tools as main effects

significantly improved the ability of the model to predict pathogenicity, adding interaction terms

between the assay result and the computational tool prediction did not. This indicates that the

predictive power of the computational tool is the same regardless of the assay result (wild-type

of LOF). Additionally, these logistic regressions did not impose an order on the predictions of the

computational tool (pathogenic or benign), however, in general we see that the resulting

coefficients reflect our expectations that pathogenic predictions are more indicative of

pathogenicity than are benign predictions. Thus, we conclude that Align-GVGD and

Alphamissense had the best-balanced performance of variant stratification by providing

statistical significance to regression models and meeting the ACMG additivity expectations, as

summarized in Table 5.

Example VUS Evaluations

To explore the impact that joint calibration of the SGE functional assay and

computational tool prediction might have on variant classification, we work through several

examples from ClinVar and/or gnomAD in Table 6. For this analysis, only substitutions with

concordant predictions from Align-GVGD and AlphaMissense are considered as these tools

performed the best in our analysis thus far. The substitutions selected include one that reaches

Likely Pathogenic, three that cover the VUS range from Hot to Cold[38], and one that reaches

Likely Benign. For two of these, p.Asp1840Ala and p.Arg1737Ile, the results from naïve

summation of functional and computational points scores would be Likely Benign, whereas the

results from joint calibration of functional and computational evidence are VUS.

DISCUSSION:

Here, we derived a maximum likelihood estimate (MLE) model that links the OR for an

analytically defined pool of sequence variants within a case-control analysis to an estimate of

the proportion of variants within that pool that are pathogenic. Bayes rule is then used to

determine the odds of pathogenicity associated with the analysis that defined the pool and

thence ACMG points. We also defined Exceptionally Conserved Ancestral Residues (ECARs),

a concept that fits within the ACMG PM1 evidence criterion, and then identified ECARs within

the RING and tBRCT domains of *BRCA1*. The MLE model was then used to evaluate the

strength of evidence for several functional assays alone, in combination with ECAR data, and in

combination with computational tool predictions, as summarized in Figure 2. This work takes an

important step in the ability to empirically test whether assertions of the strength of evidence for

different evidence types, and combinations thereof, proposed in the 2015 ACMG/AMP

guidelines are valid. And it does so in a way that takes account of effect size while avoiding

circularities inherent in analyses that are based on re-call.

Results from three *BRCA1* functional assays were examined: a saturation genome

editing (SGE) assay that examined both the RING and tBRCT domain, a mammalian 2-hybrid

(M2H) assay that examined the RING domain, and a homology directed repair (HDR) assay that

examined the coiled-coil domain through which BRCA1 interacts with PALB2. With enormous

differences in the case-control ORs calculated for non-functional versus functional missense

substitutions, the SGE and M2H assays both provide significant evidence towards sequence

variant classification, which will be discussed in greater detail below. In contrast, there was no

OR-based evidence that loss of function in the coiled-coil HDR assay predicted increase risk of

breast or ovarian cancer; moreover, null results from a structurally informed analysis of

predicted loss of function substitutions in the core alpha helix of the coiled-coil domain (amino

acids 1,400 – 1,418) weighs against the hypothesis that missense substitutions in this domain

can be pathogenic. Therefore, careful evaluation of functional assays is required prior to their

use in clinical settings and +/- 4 ACMG points should not be assigned carte blanche[6].

Using an evolutionarily deep multi-supergroup protein multiple sequence alignment of

BRCA1, BARD1, and related RING-tBRCT proteins, we identified 14 ECARs in *BRCA1* (and

BARD1). Stratification of ECAR substitutions by *BRCA1* MAVE functional assay results,

followed by analysis through the MLE model, led to three interesting observations. (1) Of 82

possible missense substitutions at an ECAR, 78 had loss of function in the SGE; the remaining

four were either indeterminate or not assessed by the SGE assay, and 2 of these had loss of

function in the M2H assay. (2) Loss of function ECAR substitutions had an OR very similar to

that of *BRCA1* nonsense substitutions; this is an example of the expected additivity between

evidence criteria, consistent with +6 ACMG points for the combination. (3) The 326 non-

functional substitutions at non-ECAR positions also have an elevated OR, but significantly lower

than that observed for substitutions at ECAR positions, corresponding to +4 points.

With the recent publication of ACMG points-based calibration of several computational

tools, including AlphaMissense, it is of interest to examine results from combining computational

tool evidence with functional assay evidence. Since ECARs fit within the PM1 evidence

criterion, yet should ideally be captured by computational tools, we avoided double counting

ECAR evidence by applying the computational tools to functional assay results at the non-

ECAR RING and tBRCT positions.

For the set of 326 non-ECAR RING and tBRCT substitutions with SGE assay loss-of-

function, the expected result is that computational tool evidence in favor of pathogenicity will

result in an analytic subset with a higher OR, adding an ACMG point(s) to the score of the input

data set. Computational tool evidence in favor of benignity should then result in an analytic

subset with a lower OR, subtracting an ACMG point(s) from the score of the input data set. Of

the six computational tools tested, only two – Align-GVGD and AlphaMissense – generated this

bidirectional pattern. Two other tools – MutPred2 and VEST4 – generated negative points with

their indeterminate and/or evidence of benignity outputs, but did not generate positive points

with their evidence of pathogenicity. It should be noted that for these non-ECARs substitutions,

concordant evidence of pathogenicity from the functional assay and either Align-GVGD or

AlphaMissense resulted in a score of +5 points, meaning that additional evidence in favor of

pathogenicity – perhaps from co-segregation or tumor features as was the case with *BRCA1*

p.Pro34Ser[7] – would be required for the variants to reach ≥ +6 points and thus Likely

Pathogenic. Under the computational tool score thresholds established in Pejvaer et al.[5, 30] for

Pathogenic Supporting (+1 ACMG point), most tools added 0 ACMG points when combined with

loss of function results (except for AlphaMissense). When these thresholds were changed to

that of Pathogenic Moderate (+2 ACMG points), no tool added +2 ACMG points on top of the

functional assay result (Table S8), which is another example of departure from simple additivity

assumed in the ACMG guidelines.

Under the logic of both the IARC/ENIGMA/InSiGHT and the Bayesian interpretation of

the ACMG/AMP sequence variant classification systems, evidence against pathogenicity has

been interpreted as evidence in favor of benignity. At the same time, both ENIGMA (Evidence-

based Network for the Interpretation of Germline Mutant Alleles) and the BRCA1/2 VCEP

(Variant Classification Expert Panel) recognize the existence of moderate-risk susceptibility

genes and moderate-risk variants of high-risk susceptibility genes (also called Reduced

Penetrance Pathogenic Variants, RPPV)[8, 19, 39]. To reduce the likelihood of generating evidence

in favor of benignity for missense substitutions that might eventually be classified as RPPVs, we

made the potentially controversial choice to estimate proportions pathogenic and ACMG points

for variants with normal function in the functional assays using moderate-risk breast and ovarian

cancer thresholds.

For the set of 1,284 RING and tBRCT missense substitutions that were functional in the

SGE assay, the ORs for breast and ovarian cancer were near 1.0, consistent with -4 ACMG

points, even if calculated with the moderate-risk threshold. Stratification of these with the set of

six computational tools revealed two trends plus an analytic difficulty. First, two of the

computational tools – BayesDel and REVEL – returned scores in favor of benignity for only a

very small fraction of these missense substitutions: 3% by BayesDel and <1% by REVEL. We

interpret this as a failure within these two tools' algorithms. Second, three of the tools – Align-

GVGD, AlphaMissense, and VEST4 – generated a bidirectional stratification, with higher ORs

and ACMG point scores associated with computational evidence of pathogenicity and lower

ORs and point scores associated with evidence of benignity. We interpret this as a subset of the

computational tools adding useful evidence towards variant classification on top of the functional

assay result. The analytic difficulty is that modest changes in the OR produced large changes in

the ACMG point scores; when the SGE assay and computational tool were discordant,

combining the two produced point scores that were beyond the range expected from simple

additivity.

The individual sequence variants evaluated in Table 6 provide examples for many of the

trends described above. For example, functional assay loss of function at an ECAR, with

concordant computational evidence, (p.Thr1700Ile) results in Likely Pathogenic. On the other

hand, loss of function at a non-ECAR position with concordant computational evidence in favor

of pathogenicity (p.Ile15Thr) results in a hot VUS, and further evidence of pathogenicity would

be required to reach Likely Pathogenic. In either scenario, evidence in favor of benignity that

might arise from human subjects data or other evidence could move variants with these

evidence combinations from Likely Pathogenic and hot VUS to hot or cool VUS respectively.   At

the other end of the spectrum, and using the moderate-risk OR threshold for calibration to

reduce the likelihood of classifying RPPVs as likely benign, an assay result of functional with

concordant computational evidence of benignity (p.Ala1823Val) results in Likely Benign. But

discordant results between a calibrated functional assay and calibrated computational tool

(p.Asp1840Ala, p.Arg1737Ile) result in cool to cold VUS – and a concern that the computational

tools need to be accurately calibrated in order to avoid this classification result for too many

missense substitutions.

Like most studies, this one had several limitations. A challenge to the ECARs

component of the approach pursued here is variable quality of assembly and subsequent

annotation of reference genomes. Thus, searches against available databases may give a

misleading view of which organisms outside of Holozoa encode genes with both RING and

tBRCT domains. Furthermore, this study was conducted on *BRCA1*, a gene that probably

shares ancestry with *BARD1*, these two representing Holozoan examples of a gene family that

has undergone a modest level of evolutionary diversification. It is not known if this method will

be applicable to genes which are members of gene families that have undergone wide

diversification or that are unique to Holozoa. Much of the subsequent results depend on case-

control estimates of OR and downstream calculations. However, carrier data were too sparse,

and the racial/ethnic categorizations between our source data too different for us to make

detailed adjustment for race/ethnicity, let alone other potentially relevant variables. These

concerns may impact the precision of our results, especially at effect sizes that are relevant to

distinctions between benign and moderate-risk missense substitutions. Finally, repeated use of

the MLE model, especially applying it at two distinctly different OR thresholds, may have

overstressed its assumption of a 2-component mixture. This concern may also impact the

precision of our results.

The MLE model coupled with a preliminary definition of ECARs allowed us to tease out

the observation that substitutions falling at the 14 *BRCA1*/*BARD1* ECAR residues contribute

disproportionate evidence of pathogenicity for missense substitutions in *BRCA1*, leading to a

hypothesis that will need to be tested with evidence from other genes. With substitutions falling

at ECAR positions set aside, Align-GVGD and AlphaMissense emerged as the two strongest

computational tools for prediction of *BRCA1* missense substitution pathogenicity. These two

tools also performed well for prediction of *BRCA1* missense substitution benignity. Since

AlphaMissense is a proteome-wide tool whereas Align-GVGD is not, this observation leads to a

recommendation in favor of the use of AlphaMissense – but also a recommendation that one of

the Meta-predictor computational tools be upgraded to include explicit recognition of ECARs, an

Align-GVGD like scoring component, and AlphaMissense itself.

The MLE model also enabled joint evaluation of functional assay and computational tool

outputs with separate OR thresholds for evidence in favor of pathogenicity and evidence in favor

of benignity. In both instances, discordant results from functional assay and computational tool

created analytical subsets of variants that may harbor variants that are actually RPPV, which

otherwise may have been incorrectly classified as high-risk Likely Pathogenic or Likely Benign.

On the benign end of the spectrum, this analysis was only possible because the BRCA1/2

VCEP has a well-defined moderate-risk threshold. As the findings from this study are applied to

other health outcomes, a critical effort will be defining similar moderate-risk thresholds for the

relevant set of genes and diseases. Doing so will enable the analytical detection of the

biological reality that disease risk is not an all or nothing outcome but rather falls on a continuum

from benign to pathogenic.

ACKNOWLEDGEMENTS:

We would like to thank Marcy Richardson, Tina Pesaran, Colin Young, and Steven Harrison

from Ambry Genetics for thoughtful discussion and database support. We would also like to

thank AC Tan, Jay Gertz, and Pinar Bayrak-Toydemir for thoughtful reading and comments on

the manuscript. This work was funded in part by NIH NCI R01CA264971, to SVT. STP is a

recipient of the NIH NCI T32CA265782.

DATA AND CODE AVAILABILITY:

Simple observational data tables are available from S.V.T. R code for the main analysis is

available from A.T.

DECLARATION OF INTERESTS:

The authors declare no competing interests.

REFERENCES:

(1) Landrum, M. J.; Lee, J. M.; Riley, G. R.; Jang, W.; Rubinstein, W. S.; Church, D. M.; Maglott, D. R. ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res* **2014**, *42* (Database issue), D980-985. DOI: 10.1093/nar/gkt1113 From NLM Medline.

(2) Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W. W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* **2015**, *17* (5), 405-424. DOI: 10.1038/gim.2015.30 From NLM Medline.

(3) Tavtigian, S. V.; Greenblatt, M. S.; Harrison, S. M.; Nussbaum, R. L.; Prabhu, S. A.; Boucher, K. M.; Biesecker, L. G.; ClinGen Sequence Variant Interpretation Working, G. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. *Genet Med* **2018**, *20* (9), 1054-1060. DOI: 10.1038/gim.2017.210 From NLM Medline.

(4) Tavtigian, S. V.; Harrison, S. M.; Boucher, K. M.; Biesecker, L. G. Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. *Hum Mutat* **2020**, *41* (10), 1734-1737. DOI: 10.1002/humu.24088 From NLM Medline.

(5) Pejaver, V.; Byrne, A. B.; Feng, B. J.; Pagel, K. A.; Mooney, S. D.; Karchin, R.; O'Donnell-Luria, A.; Harrison, S. M.; Tavtigian, S. V.; Greenblatt, M. S.; et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. *Am J Hum Genet* **2022**, *109* (12), 2163-2177. DOI: 10.1016/j.ajhg.2022.10.013 From NLM Medline.

(6) Brnich, S. E.; Abou Tayoun, A. N.; Couch, F. J.; Cutting, G. R.; Greenblatt, M. S.; Heinen, C. D.; Kanavy, D. M.; Luo, X.; McNulty, S. M.; Starita, L. M.; et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. *Genome Med* **2019**, *12* (1), 3. DOI: 10.1186/s13073-019-0690-2 From NLM Medline.

(7) Clark, K. A.; Paquette, A.; Tao, K.; Bell, R.; Boyle, J. L.; Rosenthal, J.; Snow, A. K.; Stark, A. W.; Thompson, B. A.; Unger, J.; et al. Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions. *Am J Hum Genet* **2022**, *109* (6), 1153-1174. DOI: 10.1016/j.ajhg.2022.05.004 From NLM Medline.

(8) Spurdle, A. B.; Greville-Heygate, S.; Antoniou, A. C.; Brown, M.; Burke, L.; de la Hoya, M.; Domchek, S.; Dork, T.; Firth, H. V.; Monteiro, A. N.; et al. Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. *J Med Genet* **2019**, *56* (6), 347-357. DOI: 10.1136/jmedgenet-2018-105872 From NLM Medline.

(9) Yang, X.; Wu, Y.; Ficorella, L.; Wilcox, N.; Dennis, J.; Tyrer, J.; Carver, T.; Pashayan, N.; Tischkowitz, M.; Pharoah, P. D. P.; et al. Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank. *Br J Cancer* **2024**, *131* (9), 1473-1479. DOI: 10.1038/s41416-024-02851-z From NLM Medline.

(10) Siegel, R. L.; Giaquinto, A. N.; Jemal, A. Cancer statistics, 2024. *CA Cancer J Clin* **2024**, *74* (1), 12-49. DOI: 10.3322/caac.21820 From NLM Medline.

(11) Institute, N. C. Cancer Stat Facts.

(12) Wallace, I. M.; O'Sullivan, O.; Higgins, D. G.; Notredame, C. M-Coffee: combining
multiple sequence alignment methods with T-Coffee. *Nucleic Acids Res* **2006**, *34* (6), 1692-
1699. DOI: 10.1093/nar/gkl091 From NLM Medline.
(13) Armougom, F.; Moretti, S.; Poirot, O.; Audic, S.; Dumas, P.; Schaeli, B.; Keduas, V.;
Notredame, C. Expresso: automatic incorporation of structural information in multiple
sequence alignments using 3D-Coffee. *Nucleic Acids Res* **2006**, *34* (Web Server issue),
W604-608. DOI: 10.1093/nar/gkl092 From NLM Medline.
(14) Potter, S. C.; Luciani, A.; Eddy, S. R.; Park, Y.; Lopez, R.; Finn, R. D. HMMER web server:
2018 update. *Nucleic Acids Res* **2018**, *46* (W1), W200-W204. DOI: 10.1093/nar/gky448
From NLM Medline.
(15) Tavtigian, S. V.; Byrnes, G. B.; Goldgar, D. E.; Thomas, A. Classification of rare missense
substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications.
Hum Mutat **2008**, *29* (11), 1342-1354. DOI: 10.1002/humu.20896 From NLM Medline.
(16) Young, E. L.; Feng, B. J.; Stark, A. W.; Damiola, F.; Durand, G.; Forey, N.; Francy, T. C.;
Gammon, A.; Kohlmann, W. K.; Kaphingst, K. A.; et al. Multigene testing of moderate-risk
genes: be mindful of the missense. *J Med Genet* **2016**, *53* (6), 366-376. DOI:
10.1136/jmedgenet-2015-103398 From NLM Medline.
(17) Findlay, G. M.; Daza, R. M.; Martin, B.; Zhang, M. D.; Leith, A. P.; Gasperini, M.; Janizek,
J. D.; Huang, X.; Starita, L. M.; Shendure, J. Accurate classification of BRCA1 variants with
saturation genome editing. *Nature* **2018**, *562* (7726), 217-222. DOI: 10.1038/s41586-018-
0461-z From NLM Medline.
(18) Nagy, G.; Diabate, M.; Banerjee, T.; Adamovich, A. I.; Smith, N.; Jeon, H.; Dhar, S.; Liu,
W.; Burgess, K.; Chung, D.; et al. Multiplexed assay of variant effect reveals residues of
functional importance in the BRCA1 coiled-coil and serine cluster domains. *PLoS One*
2023, *18* (11), e0293422. DOI: 10.1371/journal.pone.0293422 From NLM Medline.
(19) Parsons, M. T.; de la Hoya, M.; Richardson, M. E.; Tudini, E.; Anderson, M.; Berkofsky-
Fessler, W.; Caputo, S. M.; Chan, R. C.; Cline, M. S.; Feng, B. J.; et al. Evidence-based
recommendations for gene-specific ACMG/AMP variant classification from the ClinGen
ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel. *Am J Hum Genet* **2024**, *111* (9),
2044-2058. DOI: 10.1016/j.ajhg.2024.07.013 From NLM Medline.
(20) Esposito, D.; Weile, J.; Shendure, J.; Starita, L. M.; Papenfuss, A. T.; Roth, F. P.; Fowler,
D. M.; Rubin, A. F. MaveDB: an open-source platform to distribute and interpret data from
multiplexed assays of variant effect. *Genome Biol* **2019**, *20* (1), 223. DOI: 10.1186/s13059-
019-1845-6 From NLM Medline.
(21) Feng, B. J. PERCH: A Unified Framework for Disease Gene Prioritization. *Hum Mutat*
2017, *38* (3), 243-251. DOI: 10.1002/humu.23158 From NLM Medline.
(22) Ioannidis, N. M.; Rothstein, J. H.; Pejaver, V.; Middha, S.; McDonnell, S. K.; Baheti, S.;
Musolf, A.; Li, Q.; Holzinger, E.; Karyadi, D.; et al. REVEL: An Ensemble Method for
Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet* **2016**, *99* (4), 877-
885. DOI: 10.1016/j.ajhg.2016.08.016 From NLM Medline.
(23) Carter, H.; Douville, C.; Stenson, P. D.; Cooper, D. N.; Karchin, R. Identifying Mendelian
disease genes with the variant effect scoring tool. *BMC Genomics* **2013**, *14 Suppl 3* (Suppl
3), S3. DOI: 10.1186/1471-2164-14-S3-S3 From NLM Medline.

(24) Martin, F. J.; Amode, M. R.; Aneja, A.; Austine-Orimoloye, O.; Azov, A. G.; Barnes, I.;
Becker, A.; Bennett, R.; Berry, A.; Bhai, J.; et al. Ensembl 2023. *Nucleic Acids Res* **2023**, *51*
(D1), D933-D941. DOI: 10.1093/nar/gkac958 From NLM Medline.
(25) Liu, X.; Li, C.; Mou, C.; Dong, Y.; Tu, Y. dbNSFP v4: a comprehensive database of
transcript-specific functional predictions and annotations for human nonsynonymous and
splice-site SNVs. *Genome Med* **2020**, *12* (1), 103. DOI: 10.1186/s13073-020-00803-9 From
NLM Medline.
(26) Pejaver, V.; Urresti, J.; Lugo-Martinez, J.; Pagel, K. A.; Lin, G. N.; Nam, H. J.; Mort, M.;
Cooper, D. N.; Sebat, J.; Iakoucheva, L. M.; et al. Inferring the molecular and phenotypic
impact of amino acid variants with MutPred2. *Nat Commun* **2020**, *11* (1), 5918. DOI:
10.1038/s41467-020-19669-x From NLM Medline.
(27) Cheng, J.; Novati, G.; Pan, J.; Bycroft, C.; Zemgulyte, A.; Applebaum, T.; Pritzel, A.;
Wong, L. H.; Zielinski, M.; Sargeant, T.; et al. Accurate proteome-wide missense variant
effect prediction with AlphaMissense. *Science* **2023**, *381* (6664), eadg7492. DOI:
10.1126/science.adg7492 From NLM Medline.
(28) Tavtigian, S. V.; Deffenbaugh, A. M.; Yin, L.; Judkins, T.; Scholl, T.; Samollow, P. B.; de
Silva, D.; Zharkikh, A.; Thomas, A. Comprehensive statistical study of 452 BRCA1 missense
substitutions with classification of eight recurrent substitutions as neutral. *J Med Genet*
2006, *43* (4), 295-305. DOI: 10.1136/jmg.2005.033878 From NLM Medline.
(29) Mathe, E.; Olivier, M.; Kato, S.; Ishioka, C.; Hainaut, P.; Tavtigian, S. V. Computational
approaches for predicting the biological effect of p53 missense mutations: a comparison
of three sequence analysis based methods. *Nucleic Acids Res* **2006**, *34* (5), 1317-1325.
DOI: 10.1093/nar/gkj518 From NLM Medline.
(30) Bergquist, T.; Stenton, S. L.; Nadeau, E. A. W.; Byrne, A. B.; Greenblatt, M. S.; Harrison,
S. M.; Tavtigian, S. V.; O'Donnell-Luria, A.; Biesecker, L. G.; Radivojac, P.; et al. Calibration of
additional computational tools expands ClinGen recommendation options for variant
classification with PP3/BP4 criteria. *bioRxiv* **2024**. DOI: 10.1101/2024.09.17.611902 From
NLM PubMed-not-MEDLINE.
(31) Chen, S.; Francioli, L. C.; Goodrich, J. K.; Collins, R. L.; Kanai, M.; Wang, Q.; Alföldi, J.;
Watts, N. A.; Vittal, C.; Gauthier, L. D.; et al. A genomic mutational constraint map using
variation in 76,156 human genomes. *Nature* **2024**, *625* (7993), 92-100. DOI:
10.1038/s41586-023-06045-0.
(32) Karczewski, K. J.; Francioli, L. C.; Tiao, G.; Cummings, B. B.; Alföldi, J.; Wang, Q.;
Collins, R. L.; Laricchia, K. M.; Ganna, A.; Birnbaum, D. P.; et al. The mutational constraint
spectrum quantified from variation in 141,456 humans. *Nature* **2020**, *581* (7809), 434-443.
DOI: 10.1038/s41586-020-2308-7.
(33) Li, H.; LaDuca, H.; Pesaran, T.; Chao, E. C.; Dolinsky, J. S.; Parsons, M.; Spurdle, A. B.;
Polley, E. C.; Shimelis, H.; Hart, S. N.; et al. Classification of variants of uncertain
significance in BRCA1 and BRCA2 using personal and family history of cancer from
individuals in a large hereditary cancer multigene panel testing cohort. *Genet Med* **2020**, *22*
(4), 701-708. DOI: 10.1038/s41436-019-0729-1 From NLM Medline.
(34) Easton, D. F.; Deffenbaugh, A. M.; Pruss, D.; Frye, C.; Wenstrup, R. J.; Allen-Brady, K.;
Tavtigian, S. V.; Monteiro, A. N.; Iversen, E. S.; Couch, F. J.; et al. A systematic genetic
assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and

BRCA2 breast cancer-predisposition genes. *Am J Hum Genet* **2007**, *81* (5), 873-883. DOI:
10.1086/521032 From NLM Medline.
(35) Trapp, O.; Seeliger, K.; Puchta, H. Homologs of breast cancer genes in plants. *Front*
Plant Sci **2011**, *2*, 19. DOI: 10.3389/fpls.2011.00019 From NLM PubMed-not-MEDLINE.
(36) Keeling, P. J.; Burki, F. Progress towards the Tree of Eukaryotes. *Curr Biol* **2019**, *29* (16),
R808-R817. DOI: 10.1016/j.cub.2019.07.031 From NLM Medline.
(37) Al Jewari, C.; Baldauf, S. L. An excavate root for the eukaryote tree of life. *Sci Adv* **2023**,
9 (17), eade4973. DOI: 10.1126/sciadv.ade4973 From NLM Medline.
(38) Garrett, A.; Durkie, M.; Callaway, A.; Burghel, G. J.; Robinson, R.; Drummond, J.; Torr,
B.; Cubuk, C.; Berry, I. R.; Wallace, A. J.; et al. Combining evidence for and against
pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus
recommendations. *J Med Genet* **2021**, *58* (5), 297-304. DOI: 10.1136/jmedgenet-2020-
107248 From NLM Medline.
(39) Pal, T.; Mundt, E.; Richardson, M. E.; Chao, E.; Pesaran, T.; Slavin, T. P.; Couch, F. J.;
Monteiro, A. N. A. Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical
germline genetic testing. *NPJ Precis Oncol* **2024**, *8* (1), 247. DOI: 10.1038/s41698-024-
00741-4 From NLM PubMed-not-MEDLINE.

FIGURE LEGENDS

Figure 1. Description of Study Workflow

Functional assay results were combined with other data types (Exceptionally Conserved

Ancestral Residue (ECAR) or computational tool prediction) to evaluate the additivity

assumptions in the ACMG guidelines. Table 1: Tabulation of the number of functionally abnormal

variants (red line) that fall at ECAR positions. Table 2: A case control analysis and conversion to

ACMG points is then performed on these variants and results. Table 3: Functionally abnormal

variants that do not fall at ECAR positions are combined with predictions from six computational

tools, followed by a case control analysis and conversion to ACMG points. Table 4: Functionally

normal variants (blue line) from the assay are combined with computational tool predictions from

the same six tools, followed by a case control analysis and conversion to ACMG points.

Figure 2. Graphical Summary of Results

The matrix represents the main combinations of evidence evaluated in this study. The number in

the row or column headers represent the Bayesian point value assigned to each evidence type in

the ACMG guidelines. Each box has three lines: Expectation, Observed, and Percent of calls.

"Expectation" is the Bayesian points expected according to the ACMG guidelines. The

combination of ECAR, MAVE loss of function, and computational tool pathogenic was capped at

≥+6 points. Otherwise expected points per category are additive as described in the ACMG

guidelines. The Observed line represents the Bayesian point value that was observed using the

MLE model in this study. The Percent all calls line represents the range, as a percent, of all

possible substitutions that were observed for a particular combination of evidence for the

computational tools evaluated. Blue filled boxes indicate that the combination of evidence met or

exceeded the ACMG guideline expectations in this study. Peach filled boxes indicate that the

combination of evidence departed from the expected additivity of the ACMG guideline in this

841   study. The bold black outline highlights that the assumption that MAVE LOF and computational

842   predictions of pathogenicity are additive is not met in this study; moreover, this combination had

843   a substantial number of observations. White filled boxes represent combinations of evidence

844   with little to no data. Dark grey filled boxes represent combinations of evidence with results that

845   may be beyond the dynamic range of the MLE model.

Figure 1

Figure 2

		Substitution at ECAR (+2)		Substitution at non-ECAR (+0)	
		MAVE LOF (+4)	MAVE Functional (-4)	MAVE LOF (+4)	MAVE Functional (-4)
Computational Prediction	Pathogenic (+1)	Expectation: ≥+6 ACMG Points Observed: ≥+6 Percent of calls: (2.67% - 4.25%)	Expectation: -1 ACMG Points Observed: NA Percent of calls: (0.00%)	Expectation: +5 ACMG Points Observed: +4 to +5 Percent of calls: (6.42% - 15.24%)	Expectation: -3 ACMG Points Observed: 0 to +2 Percent of calls: (3.32% - 22.65%)
	Benign (-1)	Expectation: +5 ACMG Points Observed: NA Percent of calls: (0.00% - 0.11%)	Expectation: -3 ACMG Points Observed: NA Percent of calls: (0.00%)	Expectation: +3 ACMG Points Observed: +1 to +5 Percent of calls: (0.00% - 4.90%)	Expectation: -5 ACMG Points Observed: ≤-5 Percent of calls: (0.16% - 54.98%)

= Meets or exceeds expectations   = Departs from expected additivity   = Scant Observations

= Limited sensitivity between individual data points

Table 1. Predictions from SGE Functional Assay and Computational Tools at ECAR Positions.

Residue	Total Number of Possible snMS	LOF in SGE	Number of +4 Calls made by:					Other Models:	
			AlphaMissense	BayesDel	MutPred2	REVEL	VEST4	BayesDel-VCEP[a]	A-GVGD
Cys24	6	5	6	5	0	5	1	6	6
Cys27	6	6	4	5	0	5	0	6	6
Cys39	6	6	5	6	0	4	2	6	6
His41	7	7	2	6	0	3	0	7	5
Cys44	6	6	5	6	0	4	0	6	6
Cys47	6	6	6	6	0	2	3	6	6
Cys61	6	5	5	6	0	4	2	6	6
Cys64	6	6	4	6	0	5	4	6	6
Thr1685	5	5	0	0	0	0	0	3	1
His1686	7	7	0	0	0	0	0	6	5
Thr1700	6	5	0	0	0	0	0	6	3
Trp1718	5	4	1	5	0	2	0	5	4
Arg1753	5	5	0	0	0	0	0	5	4
Trp1837	5	5	2	5	0	0	0	5	4
Totals at ECAR positions	82	78[b]	41	56	0	34	12	79	68
Total ECAR snMS with LOF in SGE	78	78	39	53	0	32	11	75	65
Totals with LOF via SGE assay	404	404	52	67	0	33	11	301	183
Totals in RING/tBRCT domains	1,840	404	60	73	1	35	12	530	267
Totals across BRCA1	11,009	NA	60	122	1	45	12	846	314

ECAR = Exceptionally Conserved Ancestral Residue
snMS = Single Nucleotide Missense Substitution
LOF = Loss of Function
SGE = Saturation Genome Editing
VCEP = Variant Curation Expert Panel

a. VCEP thresholds divide 'BayesDel no AF' scores into supporting benign, supporting pathogenic, and indeterminate scores. Scores ≥ 0.28 are supporting pathogenic.

b. 4 variants at ECAR positions were not LOF. C24F, C61R, and W1718S had indeterminate results. T1700S was not interrogated in the assay.

Table 2. Proportions Pathogenic, and ACMG Point Estimates of Functional Assay Analytical Subsets and Non-functional Substitutions Falling at ECAR Positions. OR Threshold equal to that of nonsense variants in breast and ovarian cancer groups[a]

	Possible SNS[b]	Observed OR: Breast Cancer	Observed OR: Ovarian Cancer	M.L.E Proportion Pathogenic[c]	Estimated ACMG Point[d]	Expected ACMG Point[e]	Meets ACMG Expectations
Nonsense Substitutions	800	16.2	46.4	1 (Reference)	+8	+8	Yes
M2H Assay Categories							
Functional	452	1.42[h]	2.45[h]	0.04	-1	-4	No
Indeterminate	17	NA	NA	NA	NA	NA	
Non-Functional – All	100	19.9[h]	40.0[h]	0.99	≥+4	+4	Yes
Non-functional – ECAR	50	22.0	40.8	1.00	≥+6	+6	Yes
Non-functional – Other	50	7.82	32.9	0.70	+4	+4	Yes
SGE Assay Categories							
Functional	1,185	1.11[h]	1.34[h]	0.00	≤-4	-4	Yes
Indeterminate	148	2.17	5.29	0.12	0	0	Yes
Non-Functional – All	413	15.7	35.1[h]	0.92	≥+4	+4	Yes
Non-functional – ECAR	89	23.6	42.3	1.00	≥+6	+6	Yes
Non-functional – Other	324	12.2	31.7	0.76	+4	+4	Yes
HDR Assay Categories							
Functional	152	1.87	2.04	0.08	0	-4	No
Indeterminate	15	NA	NA	NA	NA	NA	
Non-Functional – All	16	1.58	NA	0.08	0	+4	No
A Priori Damaging[f]	22[g]	0.46	NA	0.00	-4	+2	No

ACMG = American College of Medical Genetics and Genomics
ECAR = Exceptionally Conserved Ancestral Residue
SNS = Single Nucleotide Substitution. Row 1 is the total of SNS that result in stop codons. All other rows represent single nucleotide missense substitutions.
Obs. = Observations
OR = Odds Ratio
C.I. = Confidence Interval
M.L.E = Maximum Likelihood Estimate
NA = Not Applicable

M2H = Mammilian-2-Hybrid
SGE = Saturation Genome Editing
ECAR = Exceptionally Conserved Ancestral Residue
HDR = Homology Directed Repair
a. Nonsense OR for breast cancer = 16.2, Nonsense OR for ovarian cancer = 46.4.
b. Restricted to those snMS interrogated in the assay indicated.
c. The OR threshold used for this calculation is that of the nonsense variants observed in our case/control dataset.
d. The maximum allowed points are capped as specified in ACMG variant classification guidelines per evidence category/combination of evidence categories.
e. The expected points from combining evidence categories according to ACMG guidelines.
f. This subset interrogates the substitutions to Proline and other non-conservative amino acid substitutions that fell at the a,d positions of the alpha helix in the coiled-coil domain (M1400, Q1401, H1402, L1404, L1407, Q1408, Q1409, M1411, A1412, L1414, A1416, L1418), regardless of whether they were interrogated in the assay. Only Q1401P was included in the assay and had no clinical or gnomAD observations in our dataset.
g. This is the total number of possible substitutions listed in footnote e. irrespective of inclusion in the HDR assay of the coiled coil domain.
h. Indicates that these ORs are statistically significant from one another with a p-value less than 0.0001.

Table 3. Proportions Pathogenic, and ACMG Point Estimates of Non-functional, Non-ECAR Assay Results Combined with Computational Predictions. OR Threshold equal to that of nonsense variants in breast and ovarian cancer groups[a].

Computational Tool Prediction	Possible snMS[b]	Observed OR: Breast Cancer	Observed OR: Ovarian Cancer	M.L.E Proportion Pathogenic[c]	Change in Proportion Pathogenic[d]	Estimated ACMG Point[e]	Expected ACMG Point[f]	Meets or Exceeds ACMG Expectations
A-GVGD								
Pathogenic	120	13.9	40.2	0.84	+0.08	+5	+5	Yes
Indeterminate	120	12.5	25.4	0.73	-0.03	+4	+4	Yes
Benign	91	6.06	22.1	0.56	-0.20	+3	+3	Yes
AlphaMissense								
Pathogenic	232	15.4	34.4	0.85	+0.09	+5	+5	Yes
Indeterminate	80	1.86	9.87	0.17	-0.59	0	+4	Yes
Benign	13	NA	NA	NA	NA	NA	+3	NA
BayesDel								
Pathogenic	284	12	30.1	0.75	-0.01	+4	+5	No
Indeterminate	46	15.1	52.7	0.96	+0.20	≥+5	+4	No
Benign	0	NA	NA	NA	NA	NA	+3	NA
BayesDel - VCEP								
Pathogenic	231	12.5	32.6	0.77	+0.01	+4	+5	No
Indeterminate	45	5.51	6.83	0.42	-0.34	+2	+4	Yes
Benign	55	16.2	52.7	0.98	+0.22	≥+5	+3	No
MutPred2								
Pathogenic	142	13.3	31.7	0.79	+0.03	+4	+5	No
Indeterminate	159	11.3	32	0.75	-0.01	+4	+4	Yes
Benign	29	3.7	11.54	0.29	-0.47	+1	+3	Yes
REVEL								
Pathogenic	285	11.8	29.8	0.74	-0.02	+4	+5	No
Indeterminate	46	19.6	60.1	1.00	+0.24	≥+5	+4	No
Benign	0	NA	NA	NA	NA	NA	+3	NA
VEST4								
Pathogenic	213	13.5	33.8	0.81	+0.05	+4	+5	No
Indeterminate	108	6.46	20.1	0.53	-0.23	+3	+4	Yes
Benign	10	NA	NA	NA	NA	NA	+3	NA

ACMG = American College of Medical Genetics and Genomics

ECAR = Exceptionally Conserved Ancestral Residue
snMS = Single Nucleotide Missense Substitution
Obs. = Observations
OR = Odds Ratio
C.I. = Confidence Interval
M.L.E = Maximum Likelihood Estimate
NA = Not Applicable
VCEP = Variant Curation Expert Panel
a. Nonsense OR for breast cancer = 16.2, Nonsense OR for ovarian cancer = 46.4.
b. Restricted to those snMS interrogated in the assay indicated.
c. The OR threshold used for this calculation is that of the nonsense variants observed in our case/control dataset.
d. The starting proportion pathogenic is that of the Non-ECAR, Non-functional group of variants from the SGE assay, 0.76.
e.The maximum allowed points are capped as specified in ACMG variant classification guidelines per evidence category/combination of evidence categories.
f. The expected points from combining evidence categories according to ACMG guidelines.

Table 4. Proportions Pathogenic, and ACMG Point Estimates of Functionally Normal Assay Results Combined with Computational Predictions. OR threshold equal to that of moderate risk variants[a].

Computational Tool Prediction	Possible snMS[b]	Observed OR: Breast Cancer	Observed OR: Ovarian Cancer	M.L.E Proportion Pathogenic	Change in Proportion Pathogenic	Estimated ACMG Point[c]	Expected ACMG Point[d]	Meets or Exceeds ACMG Expectations
A-GVGD								
Pathogenic	61	2.71[e]	3.73	0.83	+0.83	≥+2	-3	Yes
Indeterminate	212	1.76	1.79	0.42	+0.42	+2	-4	Yes
Benign	912	0.88[e]	1.09	0.00	0.00	≤-5	-5	Yes
AlphaMissense								
Pathogenic	122	2.12[e]	1.69	0.38	+0.38	+2	-3	Yes
Indeterminate	586	1.31	1.42	0.14	+0.14	0	-4	Yes
Benign	477	0.71[e]	1.13	0.00	0.00	≤-5	-5	Yes
BayesDel								
Pathogenic	379	1.69	1.89	0.35	+0.35	+2	-3	Yes
Indeterminate	769	0.79	0.98	0.00	0.00	≤-4	-4	Yes
Benign	37	1.67	1.97	0.28	+0.28	+1	-5	No
BayesDel - VCEP								
Pathogenic	152	1.53	1.90	0.32	+0.32	+1	-3	Yes
Indeterminate	181	1.59	1.79	0.29	+0.29	+1	-4	Yes
Benign	852	0.89	1.07	0.00	0.00	≤-5	-5	Yes
MutPred2								
Pathogenic	86	1.49	NA	0.04	+0.04	-1	-3	Yes
Indeterminate	399	1.35	1.43	0.21	+0.21	+1	-4	Yes
Benign	697	0.95	1.28	0.00	0.00	≤-5	-5	Yes
REVEL								
Pathogenic	413	1.38	1.45	0.16	+0.16	0	-3	Yes
Indeterminate	769	0.95	1.23	0.00	+0.00	≤-4	-4	Yes
Benign	3	NA	NA	NA	NA	NA	-5	NA
VEST4								
Pathogenic	116	3.43[e]	3.94[e]	1.00	+1.00	≥+2	-3	Yes
Indeterminate	763	1.18	1.40	0.13	+0.13	0	-4	Yes
Benign	306	0.57[e]	0.66[e]	0.00	0.00	≤-5	-5	Yes

ACMG = American College of Medical Genetics and Genomics

snMS = Single Nucleotide Missense Substitution

Obs. = Observations
OR = Odds Ratio
C.I. = Confidence Interval
M.L.E = Maximum Likelihood Estimate
NA = Not Applicable
VCEP = Variant Curation Expert Panel
a. The OR threshold used for this calculation is that of moderate risk variants (OR = 2 for breast cancer and OR = 2.9 for ovarian cancer) adjusted for observational inflation in our data to OR = 2.31 and OR = 3.83 respectively.
b. Restricted to those snMS interrogated in the assay indicated.
c. Positive points should be interpreted in the context of moderate risk variants. Points in favor of pathogenicity are capped at +2 to reflect this. Points in favor of benignity are capped at the lower end specified in ACMG variant classification guidelines per evidence category/combination of evidence categories.
d. The expected points from combining evidence categories according to ACMG guidelines.
e. These ORs are statistically significant from one another with a p-value less than 0.05 according to a Wald test.

Table 5. Summary of Combining SGE Functional Assay Results with Computational Tool Predictions Compared to ACMG Expectations.

Computational Tool	Addition of Computational Tool Prediction was Statistically Significant in Logistic Regression Model	Met Expectations When Combined With non-ECAR LOF Results	Met Expectations When Combined With non-ECAR Functionally Normal Results	Met Overall Expectations
AGVGD	Yes	Yes	Yes	Yes
AlphaMissense	Yes	Yes	Yes	Yes
BayesDel	No	No	No	No
BayesDel – VCEP	Yes	No	Yes	No
MutPred2	No	No	Yes	No
REVEL	No	No	No	No
VEST4	Yes	No	Yes	No

Table 6. Examples of Differences Between Naïve ACMG Addition and Jointly Calibrated Addition of Conserved Domain Data, Functional Assay Results, and Computational Tool Predictions in High-throughput Variant Classification.

BRCA1 Variant	c.5099C>T p.Thr1700Ile		c.44T>C p.Ile15Thr		c.5519A>C p.Asp1840Ala		c.5210G>T p.Arg1737Ile		c.5468C>T p.Ala1823Val	
ClinVar Overall Classification	Conflicting <u>Ambry</u>: LP <u>LabCorp</u>: Uncertain		Uncertain <u>Color</u>: Uncertain <u>LabCorp</u>: Uncertain		Uncertain <u>Invitae</u>: Uncertain		Uncertain <u>Invitae</u>: Uncertain		Not observed in ClinVar One observation in gnomAD	
Naïve ECAR Position (PM1)	Yes	+2	No	+0	No	+0	No	+0	No	+0
Naïve SGE Functional Assay Result (PS3/BS3)	LOF	+4	LOF	+4	WT	-4	WT	-4	WT	-4
Naïve Computational Tool Prediction (PP3/BP4)[a]	PP3	+1	PP3	+1	PP3	+1	Indeterminate	+0	BP4	-1
Sum of Addition of Naïve ACMG Points: ECAR + Functional Assay + Computational Tool[b]	+7		+5		-3		-4		-5	
Jointly Calibrated ACMG Points: ECAR + Functional Assay + Computational Tool[b]	+7		+5		≥+2 if using A-GVGD +2 if using AlphaMissense		+2 if using A-GVGD +0 if using AlphaMissense		≤-5	
Additional Evidence Available for High-throughput Classification										
Novel Missense Change at an Amino Acid Residue Where a Different Missense Change is Pathogenic (PM5)	+0[c]		+0[c]		+0[c]		+0[c]		+0[d]	
Case/Control Observations (PS4)[e]	+0		+0		+0[f]		+0		+0[g]	
Classification Based on Jointly Calibrated ACMG Points	LP		VUS (Hot)[h]		VUS (Cool/Cold)[h]		VUS (Cold)[h]		LB	

a. Points from computational tool predictions are limited to +1/-1 to avoid double counting of evidence contained in PM1.

b. Variants evaluated here had concordant computational tool results from A-GVGD and AlphaMissense.

c. No other variant at these locations has an overall classification of Likely Pathogenic or Pathogenic in ClinVar

d. Other variants at this amino acid residue but different nucleotide positions are classified as Likely Pathogenic or Pathogenic in ClinVar due to their impact on splicing. SpliceAI does not predict the c.5468C>T change to impact splicing[1].

e. ACMG points were calculated using the PS4 LR calculator from Rowlands et al. using the default OR threshold of 5. Although all of these variants are reported in either ClinVar or gnomAD, there were 0 case or control observations of these variants in our dataset except where noted (see f,g).[2]

f. There was one clinical observation of this missense substitution in the Myriad dataset used in Clark et al. but in the dataset used in the present analysis, which was strictly reduced to index cases with breast and/or ovarian cancer, there were no clinical observations[3].

g. There was 1 observation of this missense substitution in gnomAD.

h. Temperature ranking from Cancer Variant Interpretation Group UK Consensus Recommendations[4]